Prostate hypertrophy

Verify with FDA CVM →

VeDDRA Code: 2104

66 adverse event reports referencing this reaction

66
Total Reports
13
Deaths
1970.0%
Death Rate

Species Most Affected

Dog 66

Breeds Most Affected

Crossbred Canine/dog 8
Retriever - Labrador 7
Shepherd Dog - German 5
Beagle 4
Retriever - Golden 3
Mastiff 2
Poodle (unspecified) 2
Collie (unspecified) 2
Irish Wolfhound 2
Collie - Border 2

Associated Drugs

Milbemycin Oxime + Spinosad 11
Fluralaner Chew Tablets 11
Carprofen 9
Gabapentin 6
Enrofloxacin 6
Grapiprant 6
Famotidine 5
Oclacitinib Maleate 4
Moxidectin 4
Afoxolaner 4
Bedinvetmab 4
Prednisone 3
Cefpodoxime Proxetil 3
Cyclosporine 3
Maropitant Citrate 3
Leptospira Canicola L-15 Strain C-51;Leptospira Grippotyphosa 1550 Lot 10005 Str 3
Trilostane 3
Metronidazole 2
Cyclosporine A 2
Milbemycin Oxime 2

Data Summary

Metric Value
Total reports referencing reaction 66
Reports with fatal outcome 13
Case-fatality rate (reported events) 1970.0%
Species observed 1
Breeds observed 20
Drugs associated with reaction 20

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER); reaction term coded under VeDDRA 2104.

Prostate hypertrophy Reaction Insights

The FDA Center for Veterinary Medicine database currently lists 66 adverse event reports that reference Prostate hypertrophy as a reaction term, including 13 reports with a death outcome — a 1970.0% case-fatality figure calculated across only those events where this reaction was coded. The reaction is indexed in the openFDA system under VeDDRA code 2104, the standardized veterinary dictionary used to normalize clinical signs across submitters. Because reports are voluntary and often describe multiple concurrent signs per animal, the volume here reflects reporting intensity rather than true incidence in the broader pet population.

Prostate hypertrophy appears most frequently in reports for Dog (66 reports) — with Dog dominating at 66 entries. Within those species, the breeds most often named alongside this reaction are Crossbred Canine/dog (8), Retriever - Labrador (7), Shepherd Dog - German (5). These distributions are influenced both by underlying breed popularity and by how veterinarians and owners code a given clinical sign, so they should be interpreted as a reporting fingerprint rather than a pure susceptibility ranking.

The drugs most commonly co-reported with Prostate hypertrophy are Milbemycin Oxime + Spinosad (11 reports), Fluralaner Chew Tablets (11 reports), Carprofen (9 reports), Gabapentin (6 reports), with Milbemycin Oxime + Spinosad appearing alongside this reaction in 11 submissions. Co-reporting does not establish that any specific product caused the reaction — FDA CVM data captures temporal association only. The value of these aggregates is in flagging which therapeutic classes appear repeatedly alongside a given clinical sign, so owners and veterinarians can ask targeted questions about medications currently in use.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial